What are the adverse reactions of Bosutinib?

Bosutinib is an oral tyrosine kinase inhibitor mainly used for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Since its target involves multiple signaling pathways in cells, while inhibiting the proliferation of leukemia cells, it may also have a certain impact on normal cells. Therefore, some patients will experience varying degrees of adverse reactions during the medication. Judging from overseas drug use experience and clinical practice, the adverse reactions of bosutinib are generally predictable, and most can be alleviated through dose adjustment or symptomatic treatment.

In terms of the digestive system, diarrhea is one of the more common reactions. It usually appears in the early stages of treatment and is manifested by an increase in the number of stools or a change in stool properties. Some patients may also experience nausea, vomiting, abdominal pain or loss of appetite. Such symptoms are mostly related to the effects of drugs on the intestinal mucosa and signaling pathways. As the medication time is prolonged, the gastrointestinal tolerance of some patients will gradually improve. Proper dietary changes and necessary supportive care often help reduce discomfort.

Abnormalities related to liver function are also issues that require attention during bosutinib treatment. In some patients, elevated aminotransferases can be seen in routine tests, but most of them are reversible changes. Overseas medication guidelines generally recommend regular monitoring of liver function during the initial treatment and dose adjustment stages to detect potential risks early and intervene by briefly discontinuing medication or adjusting the dose.

In addition, bosutinib may cause skin reactions such as rash, itching, or dry skin, which are usually mild. A few patients may experience general discomfort such as fatigue, headache, or mild edema. Hematological changes, such as fluctuations in white blood cell or platelet levels, have also been reported in some populations, but the overall incidence is relatively controllable.

Keyword tags: Bosutinib adverse reactions,Bosutinib side effects, chronic myeloid leukemia medication, safety management, targeted therapy side effects

Reference materials:https://go.drugbank.com/drugs/DB06616